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Abstract
In the early twentieth century, infectious diseases were a leading cause of death worldwide.
Through the following years, morbidity and mortality caused by infectious diseases decreased
considerably in the developed world, but not in the developing world, where infectious diseases
remain an important reason for concern. For example, leishmaniosis has become into a serious
Third World problem. This is mainly due to an increasing frequency of drug-resistance in Leishmania
and an enhanced risk of co-infection with HIV. Drug-resistance is usually associated with an
increased expression of specific P-glycoproteins involved in membrane transport. The present
review summarizes information which shows that drug-resistance is also associated with changes
in physiological events such as parasite infectivity, incorporation of metabolites, xenobiotics
conjugation and traffic, intracellular metabolism, host-parasite interaction, parasite cell shape and
promastigote-amastigote differentiation. Furthermore, these events may change in a coordinated
manner. An understanding of these physiological events may be helpful for designing
chemotherapeutic approaches to multiple cellular targets, identifying strategies to circumvent
Leishmania drug-resistance and succesfully treating leishmaniosis.
Introduction
Infection by Leishmania gives rise to a variety of clinical
manifestations classically labelled as visceral, cutaneous
and mucocutaneous leishmaniosis, and chemotherapy is
the usual therapeutic approach against this disease [1]. In
order to interfere with the normal development of an
intracellular parasite, a drug must reach the compartment
where the parasite lives; death of the parasite then occurs,
either directly or through various cell-killing mechanisms
triggered by the active drug in the host cell. The complex
life cycle of Leishmania  and the intracellular nature of
some of its developmental stages make such a task more
difficult. Furthermore, as some species of Leishmania
migrate to various tissues, they can be associated with all
types of leishmanial diseases [2]. The antimoniates, which
are the clinical drugs most frequently employed against
leishmaniosis, have been in use since the 1920's. How-
ever, antimoniates have a narrow therapeutic window due
to their toxicity, and there are additional conditions
which permit the persistence of Leishmania in the verte-
brate host. In fact, the World Health Organization (WHO)
[3] has pointed out that the incidence of leishmaniosis
has increased since the 1980's, and that leishmaniosis has
gained a relevant position worldwide among the causes of
death by infectious diseases. This may be due at least
partly to the following facts: a) the risk of co-infection
with HIV and parasites causing visceral leishmaniosis is
increasing at a high rate [3], b) sub-optimal doses of the
drugs employed may induce drug-resistance, and c) lack
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of response of Leishmania to various drugs occurs with
high and increasing frequency [4–6].
The emergence of drug-resistant Leishmania  and the
increasing spread of naturally drug-resistant species stress
the importance of identifying the mechanisms directly
involved in drug-resistance, as well as the physiological
changes that may occur in Leishmania as a consequence of,
or concomitantly with, the development of drug-resist-
ance. Such physiological changes, whether or not related
to drug-resistance mechanisms, contribute to the overall
characteristics of the drug-resistant phenotype, and new
chemotherapeutic strategies against leishmaniosis could
be devised if a comprehensive understanding of drug-
resistance were obtained. The significance and relevance
of these physiological changes are the main subject of the
present review. For the sake of completeness, the genes
associated with drug-resistance in Leishmania  are also
reviewed.
The life cycle of Leishmania
All Leishmania  species are morphologically similar and
display two main developmental stages through their life
cycle: the amastigote, that resides inside the reticuloen-
dothelial cells of the vertebrate host, and the promastig-
ote, that replicates in the gut of a phlebotomine sandfly
[3,7]. The life cycle can be considered to begin when the
vertebrate host is bitten by an infected insect (see Fig. 1).
High densities of infectant parasites block the cardial
valve at the digestive tract of the sandfly and, as the insect
swallows the blood from the host, it expels the valve's
content, including the parasites. The insect's saliva con-
tains chemical factors that potentiate the parasite infective
power and exert a chemotactic effect upon reticuloen-
dothelial cells, which are attracted to the place of innocu-
lation. The parasites are then phagocyted by
reticuloendothelial cells, and this fosters their reproduc-
tion and survival. For dermotropic Leishmania species the
lesion remains in the skin, but for viscerotropic Leishma-
nia the parasite spreads from the initial skin lesion into
liver, spleen and bone marrow. The parasites profusely
replicate inside the reticuloendothelial cells and eventu-
ally burst free from the infected macrophages, spreading
the disease within the mammal host (Fig. 1). It is still not
clear whether the host cells are actively involved in this
event, are physically disrupted by the infection, or
undergo apoptosis [8,9]. As a new insect bites an infected
vertebrate host, it swallows infected macrophages, and the
parasites differentiate into promastigotes, migrate into the
midgut, become metacyclic (infective parasites) during
the next four to seven days, and migrate to the cardial
valve ready to be re-inoculated into a vertebrate host.
Physical and chemical differences among the hosts where
Leishmania lives impose radically different stress condi-
tions that must be circumvented by the parasite's ability to
adapt to diverse environments. In fact, during the devel-
opment of the promastigote stage, its transformation into
the metacyclic promastigote, its interaction with the host
cell and the establishment of the infection, the parasite is
continually activating physiological responses which
guarantee its survival. There are presently insufficient
studies on how the development of drug-resistance inter-
acts with the physiological events that trigger and regulate
the parasite's differentiation through its life cycle. The
amastigote is the cellular form relevant for human disease
(Fig. 1), but pure amastigotes are difficult to obtain in suf-
ficient number for research. It is possible, however to take
advantage of the physiological equivalence between the
so-called "axenic amastigotes" and lesion-derived amas-
tigotes [10]. Axenic amastigotes have been successfully
obtained by exposing promastigotes in vitro to extreme
temperature and pH [11]. Their transformation into
amastigote-like parasites is concomitant with cellular
changes that include the expression of specific stage pro-
teins on their surface [10,12,13].
Treatment of leishmaniosis
As already mentioned, chemotherapy constitutes the
main tool for the control of leishmaniosis, but it is usually
slow, expensive and toxic. The available antileishmanial
drugs, such as sodium stibogluconate, contain pentava-
lent antimony, act upon the amastigote and, in order to be
effective, should be administered over 20 or more days
either intravenously, for both visceral and cutaneous
leishmaniosis, or intralesionally in cutaneous leishmani-
osis [3]. The antimoniates were empirically developed
more than 80 years ago and their mechanism of action has
remained elusive. When these drugs are ineffective, or
cannot be prescribed, treatment with amphotericin B,
pentamidine or paramomycin is indicated. In general, all
present forms of treatment show unsatisfactory features,
hence the importance of developing inexpensive, effective
and rapid therapies both for visceral and for cutaneous
leishmaniosis. For example miltefosine, an inhibitor of
sterol biosynthesis, has been recently approved as the first
oral drug for visceral leishmaniosis in India. It yields cure
rates of about 98 %, has negligible side effects and is used
successfully to treat cases resistant to antimoniates [14].
Unfortunately, Leishmania can develop resistance to milte-
fosine, at least in vitro [15].
Drug-resistant cell lines, selection methods, 
implications
In general, resistance is defined as a decline in the efficacy
of a drug against a population of parasites previously sus-
ceptible to that compound. This definition assumes that
the original susceptibility of the population is known,
which is not always the case for Leishmania. Indeed, resist-
ance of Leishmania against a given drug may be eitherKinetoplastid Biology and Disease 2003, 2 http://www.kinetoplastids.com/content/2/1/14
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natural, or may be acquired when the parasites are
exposed to sub-optimal drug doses [16]. Resistant pheno-
types selected in vitro are usually obtained by culturing
wild-type parasites under stepwise increasing drug con-
centrations. The wild-type parasites may be either hetero-
geneous (non-cloned) parasites or isolated cloned
colonies with high genetic homogeneity. It is possible,
particularly in non-cloned colonies, that unexpected phe-
notypic characteristics are expressed by the majority of
parasites. Care must of course be taken not to adscribe
such characteristics to a subsequently developed drug-
resistance.
Genomic events associated with drug-resistance 
in Leishmania
As in the case of tumor cells, drug-resistance in Leishmania
has been frequently associated with decreased cellular
accumulation of the drugs. Several hypotheses for
decreased drug accumulation in resistant parasites have
been proposed, including one analogous to the drug
efflux pump model of drug-resistant tumor cells. The
increased expression of a conserved type of protein called
P-glycoprotein (P-gp) has been one of the most consistent
changes detected in drug-resistant tumor cells [17]. P-gp
belongs to the ABC transporter family, a designation asso-
ciated with the existence of a highly conserved intracellu-
lar domain that specifically binds ATP [18]. Besides its
The Leishmania life cycle Figure 1
The Leishmania life cycle. The Leishmania life cycle begins when the vertebrate host is bitten by the infected insect. Then the 
inoculated parasites are phagocyted by the reticuloendothelial cells, the intracellular parasites replicate, and eventually burst 
free from the infected macrophages, spreading the disease within the mammal host. As a new insect bites an infected verte-
brate host, it swallows infected macrophages, the parasites are then released, differentiate into promastigotes, migrate into the 
midgut, become metacyclic (infective parasites) during the next four to seven days and migrate to the cardial valve ready to be 
re-inoculated into a vertebrate host.
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role in drug efflux, P-gp has been implicated in the elimi-
nation of compounds from the cell plasma membrane,
steroid hormone secretion, phospholipid distribution,
and ATP transport [19]. Over-expression of P-gp occurs as
a result of chemotherapy but, since P-gp has been found
in normal cells, its physiological and pathological signifi-
cance is as interesting as the question of whether and how
it can be targeted to improve therapy [20].
Although multidrug-resistant (MDR) cell lines which do
not express P-gp have been isolated, the expression of P-
gp and the efflux of drugs against a concentration gradient
usually increase in sensitive cells transfected with mouse
or human P-gp cDNA [21]. Alternatively, an altered mem-
brane partition model for decreased drug accumulation in
drug-resistant cells has become popular [22]. This model
suggests that decreased drug accumulation is the result of
alterations in pH gradients, electrical membrane potential
and perhaps other biophysical parameters, and is not nec-
essarily a direct result of drug trafficking [22].
As will be presented in the following paragraphs, the use
of gene technology has yielded findings related to gene
mutation, translocation and amplification which are rele-
vant for Leishmania  drug-resistance. Table 1 presents a
summary of the genes associated with drug-resistance in
Leishmania. As will be discussed immediately, several of
these genes are related to transport molecules in the
plasma membrane.
Table 1: Genes associated to drug resistance in Leishmania
Species Gene Resistance to Cross resistance Reference
L. amazonensis lamdr vinblastine adriamycin [73]
vinblastine
doxorubicin [39]
actinomycin-D
KDNA pentamidine [64]
ribonucleotide
reductase hydroxyurea [74]
gene
NAGT tunicamycin [51]
L. donovani ldNTt1.1 tubericidin [41]
ldmdr1 vinblastine puromycin
anthracyclins [40,42]
methotrexate [43]
IMPDH mycophenolic acid [53]
L. enriettii lemdr vinblastine puromycin [37]
L. infantum H-circle methotrexate [75]
L. major H-circle primaquine methotrexate [28]
terbinafine
SQS1 terbinafine
SQS1 itraconazole
TOR tubericidin [54,63]
TUB2 tubericidin
DHFR-TS antifolates
PTR1 antifolates
L. tarentolae H-circle methotrexate [23,24]
ltpgpA-E vinblastine
arsenite [25–27,33]
antimoniates
gsh arsenite [57]
Cyb antimycin-A [70]
DHFR-TS folates
Ltdth methotrexate [31,36,52]
PTR1
L. tropica ltpgpE methotrexate [76]
ltmdr daunomycin [38]Kinetoplastid Biology and Disease 2003, 2 http://www.kinetoplastids.com/content/2/1/14
Page 5 of 10
(page number not for citation purposes)
The first MDR gene homologue discovered in Leishmania,
ltpgpA, was an extra chromosomal circle (H-circle) ampli-
fied in a methotrexate-resistant L. tarentolae promastigote
cell line [23,24]. Since then, a group of genes belonging to
the P-gp gene family and whose gene products confer low
levels of resistance to vinblastine, arsenite and trivalent
antimoniates have been characterized in L. tarentolae and
L. major [25–27]. These genes are also amplified in cell
lines resistant to terbinafine and primaquine [28]. The
structural conformation of their gene products is similar
to that of other P-gp genes, with two hemiproteins, each
with six membrane segments, 22 % homology to the
human mdr1 gene product and high levels of homology
with the multidrug associated protein (MRP) [29]. Trans-
fection of ltpgpA  into sensitive parasites triggers an
increase in the levels of polyamines and trypanothione
and a decrease in the accumulation of pentostam [30–33].
The protein products of these genes play important roles
as intracellular metal-thiol-transporter ATPases in the
early steps of resistance [34]. In other studies, L. tarentolae
promastigotes stepwise selected for resistance to sodium
stibogluconate, and mutants resistant to antimony-con-
taining drugs and cross-resistant to arsenite, showed
amplification of a locus without significant homology to
sequences previously described [35]. Recently, in meth-
otrexate-resistant L. tarentolae a deletion of folic acid trans-
porters has also been demonstrated [36].
A gene related to P-gp in Leishmania is mdr1; its expression
is frequently increased in cells with the MDR-phenotype,
a result confirmed by transfection experiments in L. enri-
etti [37]. L. tropica resistant to daunomycin over-express,
as an extra chromosomal circular location, an MDR-like
gene, ltmdr1, thus implicated in the decreased accumula-
tion of the drug in resistant parasites [38]. In L. amazonen-
sis  the longest open reading frame of the lamdr1  gene
encodes a protein consisting of two similar halves, each
containing six putative transmembrane domains and one
ATP-binding domain. These two halves are 91 and 78%
identical, respectively, to the closely related ldmdr1 in L.
donovani and lemdr1 in L. enriettii [39]. Transfection of
lamdr1 to wild-type parasites conferred a significant level
of resistance to vinblastine, doxorubicin, and actinomy-
cin-D. This drug specificity of lamdr1 overlaps with, but is
distinct from, that of ldmdr1, thus suggesting a functional
diversity of mdr1-derived proteins among different Leish-
mania species.
In L. donovani, selection and isolation under the pressure
of tubericidin led to the characterization of a resistant cell
line which showed impaired drug transport through the
plasma membrane [40]. Since tubericidin enters the cell
through nucleoside transporters, point mutations in stra-
tegic transporter sites were suggested [41]. Other studies
have also shown that vinblastine-resistant L. donovani dis-
plays cross-resistance to puromycin and anthracyclines
and shows amplification of DNA fragments homologous
to the mammalian MDR [42]. It has also been found that
methotrexate-resistant L. donovani is deficient in folate-
methotrexate transporters [43].
Pentamidine drug-resistance has been shown to be linked
to a decreased accumulation of this compound, accompa-
nied by a decreased transport of structurally unrelated
molecules such as pyrimidine nucleotide as well as by
alterations of the polyamine levels [44]. A DNA fragment
which hybridized to ltpgpA  and showed size polymor-
phism between the sensitive and the resistant strain was
amplified [46] in L. mexicana made resistant to glibencla-
mide – a general blocker of ABC transporters including P-
gp from different drug-resistant cell lines [45]. This ampli-
fication correlates with increased expression of a 185 kDa
protein band in the resistant strain, faintly expressed in
the sensitive strain [47], that was recognized by the anti-
body (F4) against the N-terminal of P-gp.
The availability of gene transfection technology in Leish-
mania originated from studies related to the amplification
of the dihydrofolate reductase gene (dhfr-ts) in methotrex-
ate-resistant parasites as well as to the design and creation
of shuttle vectors for stable transfection and expression of
foreign DNA in these parasites [48,49]. The use of shuttle
vectors has yielded findings that are relevant for Leishma-
nia drug-resistance. These findings may be related to drug
transport phenomena, as presented in the previous para-
graphs, or may be unrelated to drug transport but never-
theless relevant for Leishmania drug-resistance, as will be
presented forthwith. For example, L. mexicana made
resistant to tunicamycin, a drug that selectively inhibits
the enzyme N-acetylglucosamine-1-phosphate transferase
(NAGT), has been shown to express higher copy numbers
of an extracellular 63 kilobase (Kb) circular amplicon
[50]. By means of DNA fragment transfection, a 15 Kb
clone was described to confer tunicamycin-resistance to
wild-type L. amazonensis [51]. The minimal 4.6 Kb region
necessary to confer tunicamycin resistance was shown to
code for NAGT, and the different transfectants overpro-
duced a NAGT transcript of identical size [51]. As a conse-
quence of methotrexate resistance, L. tarentolae
preferentially shows amplification of the H locus (ltpgpA)
and the pterin reductase gene (ptr1); in L. tarentolae made
mutant for the H locus there is amplification of the dihy-
drofolate reductase-thymidylate synthase, or R locus [52].
Furthermore, transfection experiments using shuttle vec-
tors with ptr1 at the R locus and dhfr-ts at the H locus have
shown that ptr1 gave higher levels of methotrexate resist-
ance than dhfr-ts, and that ptr1 was invariably amplified -
when present- while dhfr-ts was only amplified when ptr1
was inactivated [52]. These experiments demonstrated
that both the locus and the gene determine the frequencyKinetoplastid Biology and Disease 2003, 2 http://www.kinetoplastids.com/content/2/1/14
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of gene amplification in Leishmania. In L. donovani resist-
ance to mycophenolic acid, a potent inhibitor of the ino-
sine monophosphate dehydrogenase (IMPDH), is
associated with the amplification of a stable linear extra-
chromosomal DNA (280 Kb in size) that codes for the
IMPDH gene [53]. This extrachromosomal element was
subjected to large-sized deletions of its central region and
the resulting size-reduced DNA elements were cloned into
vectors. These vectors were transfected into mycophenolic
acid-resistant Leishmania cells. The mitotic stability of the
mutated DNA elements was then analysed over 140 days
in drug-free cultures. The largest deletions (DNA frag-
ments of 120 and 200 Kb) altered the mitotic stability and
led to a progressive loss of the size-reduced DNA ele-
ments. A 30 Kb region common to both deletions was
considered as involved in mitotic stability and associated
to stable drug-resistance in Leishmania. However,
sequence analysis did not show elements typical of cen-
tromeric DNA, thus suggesting that the mitotic stability of
the DNA element was not associated to the presence of a
centromere [53]. Finally, proteomics has been used to
identify and analyse an overexpression of PTR1 in meth-
otrexate-resistant L. major [54]. This constitutes the first
proteomic analysis of drug-resistance in a parasite and
also the clearest identification of a primary drug-resistance
mechanism by means of this approach [54].
Physiological events associated with drug-
resistance in Leishmania
As will be presented herein, there are cellular events that
occur along with Leishmania drug-resistance that include
changes in xenobiotics conjugation and traffic, cytoskele-
ton phosphorylation, membrane microviscosity and com-
position, metacyclogenesis and infectivity, and
mitochondrial gene expression. It is still unclear whether
these events are central to the expression of drug-resist-
ance or rather constitute epiphenomena not directly
related to drug-resistance. Also unclear is whether these
events depend on the amastigote itself or are instead
related to the expression of drug-resistance within the
patient. Nevertheless, a comprehensive understanding of
these physiological characteristics of drug-resistant Leish-
mania seems fundamental for the treatment and control
of leishmaniosis.
Resistant species of L. tarentolae accumulate less arsenite
than wild-type cells [55]and yet in vitro experiments have
shown no difference in the rate of arsenite accumulation
in everted plasma membrane-enriched vesicles prepared
from wild-type or from arsenite-resistant cells [56]. In
resistant promastigotes, however, there is an increased
synthesis of the substrate for the transporters as well as of
trypanothione, the thiol involved in the arsenical conju-
gation and extrusion [30,32,33]. This suggests that
increased synthesis of the substrate rather than an
increased number of membrane transporters might con-
stitute a different and novel mechanism of drug-resist-
ance. This also suggests that arsenite-resistance might be
mediated by a multigen mechanism which involves
ltpgpA, the enzyme gamma-glutamylcysteine synthetase
(GSH) at the rate limiting step of glutathione biosynthesis
[56], and a transporter which actively extrudes As (III) glu-
tathione [57]. Such a multigen mechanism of drug-resist-
ance has also been observed in vinblastine-resistant
Leishmania [37,42,58].
In an arsenite-resistant L. donovani, the level of α tubulin
expression is similar between wild-type and resistant pro-
mastigotes selected from non-cloned parasites. Differenti-
ation into axenic amastigotes caused differences in the
levels of tubulin expression between the two strains [59].
More interestingly, α and β tubulin phosphorylation was
highly increased in the resistant strain [60]. It is well
known that microtubules (and tubulin) play important
roles in leishmanial proliferation, cell shape and differen-
tiation [61], and the aforementioned results suggest that
the expression of drug-resistance could alter either the
tubulin proteins themselves or the events leading to
cytoskeletal changes that occur during parasite differenti-
ation. As the two strains expressed different sensitivities to
paclitaxel -a drug that promotes tubulin assembly-, these
results suggest that changes in the expression of structural
genes and in the signal transduction cascades might be
related to drug sensitivity [60,61].
In L. donovani promastigotes resistant to amphotericin-B a
decreased influx and an increased efflux of the drug, as
well as a lower membrane microviscosity, have been dem-
onstrated [62]. Notably, the prevalent lipids in resistant L.
donovani cell plasma membrane were saturated fatty acids
and an ergosterol precursor, cholesta-5,7,24-trien-3 β-ol,
instead of the ergosterol normally found in wild-type par-
asites. On the other hand, in terbinafine-resistant L. major
an increased expression of ergosterol biosynthetic inter-
mediates was demonstrated [63]. Finally, in pentamidine-
resistant L. amazonensis alterations in membrane fluidity,
lipid content and loss of pentamidine binding sites have
been described [64]. These results suggest that an altered
membrane fluidity and changes in the extracellular expo-
sure of receptor molecules may be relevant for drug sensi-
tivity in resistant parasites [62–64].
Results presented by Sereno and Lemesre [65] indicate
that no difference in the in vitro infectivity for resident
mouse macrophages is observed between wild-type and
pentamidine-resistant clones, but decreased in vivo and in
vitro  infectivity has been described in drug-resistant L.
donovani [59], L. guyanensis [66] and L. mexicana amazon-
ensis [47,67]. Decreased lectin-induced parasite agglutina-
tion is associated with a decreased infectivity, at least in L.Kinetoplastid Biology and Disease 2003, 2 http://www.kinetoplastids.com/content/2/1/14
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guyanensis [66], as well as with a decreased expression of
the L. mexicana meta-1 protein, indicative of metacyclo-
genesis in L. major [68] (Silva, N., Camacho, N., Figarella,
K and Ponte-Sucre, A., in preparation). In this context, the
activity of acid phosphatase, an enzyme which has been
described as a virulence marker in Leishmania  [69],
decreased significantly in resistant L. mexicana [47]. Also,
there are alterations in lipophosphoglycan expression in
pentamidine-resistant parasites [64] as well as an altered
pattern of serine residue phosphorylation in L. mexicana
resistant to ABC transporter blockers [47]. Altogether
these results suggest that the development of drug-resist-
ance in Leishmania might involve alterations in its differ-
entiation into metacyclic infective parasites.
In pentamidine-resistant parasites a modification of mito-
chondrial membrane potential has been demonstrated
[64]. Also, a point mutation in the mitochondrial apocy-
tochrome b (Cyb) gene has been associated to antimycin-
A resistance in L. tarentolae [70]. However, in L. mexicana
amazonensis there were no significant differences in respi-
ration rate and cellular ATP content between arsenite-
resistant and wild-type cells [71]. These result suggest that
the mitochondrial genome might mutate as a conse-
Physiological events associated with drug-resistance in Leishmania Figure 2
Physiological events associated with drug-resistance in Leishmania. The physiological events associated with drug-
resistance in Leishmania include changes in P-gp expression, parasite infectivity (lipophosphoglycan, acid phosphatase and meta-
1 expression), incorporation of metabolites fundamental for the parasite survival (folates and nucleosides), xenobiotics conju-
gation and extrusion (trypanothione and Cyb expression), intracellular metabolism (dihydrofolate reductase-thymidylate syn-
thetase, N-acetylglucosamine-1-transferase and pterin transferase), host-parasite interaction (membrane fluidity) and parasite 
cell shape and promastigote-amastigote differentiation (tubulin phosphorylation). Black arrows indicate whether a given param-
eter is increased or decreased in the resistant parasite.
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quence of drug pressure but respiration and ATP seem not
to be prime events associated with drug-resistance.
Conclusion
The emergence of drug-resistance represents one of the
most serious problems in the control of infectious dis-
eases. Treatment failure in kala-azar, mucosal leishmanio-
sis and some forms of cutaneous leishmaniosis, occurring
in 50–70 % of the patients [72], is becoming a common
problem in many endemic areas. In some cases, this could
be attributed to altered drug pharmacokinetics, reinfec-
tion, or immunologic compromise of the host. However,
there are now strong indicators which suggest that it may
be partly due to drug-resistance [72]. Results summarized
in the present review show that the overexpression of
membrane-bound ATP binding cassette proteins is linked
to drug-resistance in Leishmania. These transport systems
modulate the efflux or intracellular trafficking of chemo-
therapeutic agents. Furthermore, the development of
drug-resistance includes alteration of other biochemical
and physiological parameters. As summarized in Fig. 2,
mechanisms described so far involve fundamental physi-
ological functions such as drug transport (MDR and
MRP), parasite's infectivity (lipophosphoglycan, acid
phosphatase and meta-1 expression), incorporation of
metabolites considered to be fundamental for the parasite
survival (folates and nucleosides), xenobiotics conjuga-
tion and traffic (trypanothione and Cyb expression),
intracellular metabolism (dihydrofolate reductase-thymi-
dylate synthetase, N-acetylglucosamine-1-transferase and
pterin transferase), host-parasite interaction (membrane
fluidity and lectin agglutination) and parasite cell shape
and promastigote-amastigote differentiation (tubulin
phosphorylation). More interestingly, mechanisms other
than the frequent amplification of transport systems
mediated by MDR or MRP are preferentially linked; this is
the case of the pterin transferase gene and the dihydro-
folate reductase-thymidylate synthetase complex in meth-
otrexate-resistant parasites, or the gamma-
glutamylcysteine synthetase enzyme and a transporter
which actively extrudes As (III) glutathione in arsenite-
resistant parasites.
These data highlight the large effort that has been invested
in understanding the changes associated with drug-resist-
ance in Leishmania, but questions still unanswered are
whether these physiological events a) are central to the
expression of drug-resistance, b) constitute epiphenom-
ena not directly related to drug-resistance, c) are expresed
by cloned promastigotes before being selected, d) are
expressed by the amastigote and therefore affect the intra-
cellular survival of the parasite, and e) are related to the
expression of drug-resistance within the patient. Never-
theless, it is hoped that knowledge of such variety of phys-
iological mechanisms will be translated into a more
effective treatment and control of leishmaniosis.
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